Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Recent Advances in Mechanisms of Resistance and Targeted Therapy in...
share announcement

Recent Advances in Mechanisms of Resistance and Targeted Therapy in Melanoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 4584

Special Issue Editors

Prof. Dr. Andreas Behren

E-Mail Website
Guest Editor
1. Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia
2. School of Cancer Medicine, La Trobe University, Bundoora, VIC 3086, Australia
3. Department of Medicine—Austin, Melbourne Medical School, University of Melbourne, Parkville, VIC 3010, Australia
Interests: cancer-immune crosstalk; EMT, innate immunity; antigen presentation; immunotherapy
Dr. Jessica Da Gama Duarte

E-Mail Website
Guest Editor
1. Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia
2. School of Cancer Medicine, La Trobe University, Bundoora, VIC 3086, Australia
Interests: B cells; circulating antibodies; protein microarrays; tumour immunology; cancer biomarkers; immunotherapy; melanoma

Special Issue Information

Dear Colleagues,

The treatment landscape of melanoma continues to rapidly evolve, with kinase inhibitors and anti-PD-1 representing the backbone of most therapeutic approaches. While highly effective, intrinsic, and acquired resistance remains a challenge, and hence, novel targeted therapies and immunotherapies administered as mono- or combination therapies, changed treatment sequencing and dosing are currently being investigated. Biomarkers to predict response are still not well established for the various treatment regimens, and novel methods to interrogate biospecimen from patients are constantly developed and tested.

In this Special Issue entitled “Recent Advances in Mechanisms of Resistance and Targeted Therapy in Melanoma”, we are asking for manuscripts reporting original data, novel methods, case studies, or updated literature reviews focused on novel treatments, understanding mechanisms of therapeutic resistance or biomarker research. All currently administered or researched targeted treatments are of interest, including those administered in combination with immunotherapeutics.

Prof. Dr. Andreas Behren
Dr. Jessica Da Gama Duarte
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • targeted therapy
  • immunotherapy
  • combination therapy
  • resistance
  • biomarkers
  • methods
  • rational combinations

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1685 KiB  
Article
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
by Carl Maximilian Thielmann, Johanna Matull, Sebastian Roth, Jan-Malte Placke, Eleftheria Chorti, Anne Zaremba, Georg Lodde, Philipp Jansen, Frederik Krefting, Julia Kretz, Inga Möller, Antje Sucker, Annette Paschen, Elisabeth Livingstone, Lisa Zimmer, Selma Ugurel, Dirk Schadendorf, Eva Hadaschik and Klaus G. Griewank
Cancers 2022, 14(9), 2090; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14092090 - 22 Apr 2022
Cited by 5 | Viewed by 1599
Abstract
(1) Background: Melanoma has the highest mortality of all cutaneous tumors, despite recent treatment advances. Many relevant genetic events have been identified in the last decade, including recurrent ARID1A mutations, which in various tumors have been associated with improved outcomes to immunotherapy. (2) [...] Read more.
(1) Background: Melanoma has the highest mortality of all cutaneous tumors, despite recent treatment advances. Many relevant genetic events have been identified in the last decade, including recurrent ARID1A mutations, which in various tumors have been associated with improved outcomes to immunotherapy. (2) Methods: Retrospective analysis of 116 melanoma samples harboring ARID1A mutations. Assessment of clinical and genetic characteristics was performed as well as correlations with treatment outcome applying Kaplan–Meier (log-rank test), Fisher’s exact and Chi-squared tests. (3) Results: The majority of ARID1A mutations were in cutaneous and occult melanoma. ARID1A mutated samples had a higher number of mutations than ARID1A wild-type samples and harbored UV-mutations. A male predominance was observed. Many samples also harbored NF1 mutations. No apparent differences were noted between samples harboring genetically inactivating (frame-shift or nonsense) mutations and samples with other mutations. No differences in survival or response to immunotherapy of patients with ARID1A mutant melanoma were observed. (4) Conclusions: ARID1A mutations primarily occur in cutaneous melanomas with a higher mutation burden. In contrast to findings in other tumors, our data does not support ARID1A mutations being a biomarker of favorable response to immunotherapies in melanoma. Larger prospective studies would still be warranted. Full article
(This article belongs to the Special Issue Recent Advances in Mechanisms of Resistance and Targeted Therapy in Melanoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 694 KiB  
Review
Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives
by Magdalena Olbryt
Cancers 2022, 14(9), 2315; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14092315 - 06 May 2022
Cited by 6 | Viewed by 2052
Abstract
Melanoma is the most aggressive skin cancer, the number of which is increasing worldwide every year. It is completely curable in its early stage and fatal when spread to distant organs. In addition to new therapeutic strategies, biomarkers are an important element in [...] Read more.
Melanoma is the most aggressive skin cancer, the number of which is increasing worldwide every year. It is completely curable in its early stage and fatal when spread to distant organs. In addition to new therapeutic strategies, biomarkers are an important element in the successful fight against this cancer. At present, biomarkers are mainly used in diagnostics. Some biological indicators also allow the estimation of the patient’s prognosis. Still, predictive markers are underrepresented in clinics. Currently, the only such indicator is the presence of the V600E mutation in the BRAF gene in cancer cells, which qualifies the patient for therapy with inhibitors of the MAPK pathway. The identification of response markers is particularly important given primary and acquired resistance to targeted therapies. Reliable predictive tests would enable the selection of patients who would have the best chance of benefiting from treatment. Here, up-to-date knowledge about the most promising genetic and non-genetic resistance-related factors is described. These are alterations in MAPK, PI3K/AKT, and RB signaling pathways, e.g., due to mutations in NRAS, RAC1, MAP2K1, MAP2K2, and NF1, but also other changes activating these pathways, such as the overexpression of HGF or EGFR. Most of them are also potential therapeutic targets and this issue is also addressed here. Full article
(This article belongs to the Special Issue Recent Advances in Mechanisms of Resistance and Targeted Therapy in Melanoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop